Jin et al. reported that receptor tyrosine kinase inhibitors increased Bcl-2 expression levels in cancer cell lines, and this was considered a resistance mechanism of cancer cells against tyrosine kinase inhibitors [31]. The gene discussed is NTRK1; the disease is cancer.